All In Biotech

Drug Trial Radar · NCT04224987

Azithromycin for Child Survival in Niger: Mortality and Resistance Trial

Azithromycine Pour la Vie Des Enfants au Niger - Implémentation et Recherche: Essai mortalité et résistance (Azithromycin for Child Survival in Niger: Mortality Trial and Resistance Trial)

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 864,493 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

864,493

Actual

Start

Nov 24, 2020

Primary completion

Jul 31, 2024

Study completion Jul 31, 2024

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; Ministry of Health, Niger
First posted
Jan 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 59 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings.Targeting treatment to children 1-11 months old could reduce antimicrobial resistance by limiting antibiotic distributions while treating children at the highest mortality risk. However, this targeted intervention has not yet been tested. The AVENIR mortality/resistance trial aims to assess the efficacy of age-based targeting of biannual azithromycin distribution on mortality as well as determine the impact of age-based targeting on antimicrobial resistance.

Conditions

  • Mortality
  • Resistance Bacterial
  • Child, Only

Interventions

  • AzithromycinDrug

    Azithromycin will be administered as a directly observed dose in oral suspension form for children: 1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g) 2. For children 1-11 months of age, weight or age-based dosing will be used 3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program

  • PlaceboOther

    Placebo will be administered as a directly observed dose in oral suspension form for children: 1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g) 2. For children 1-11 months of age, weight-based dosing will be used 3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause Mortality (1-59 Months Old)Time frame: from 6 months up to 2.5 years
  2. All-cause Mortality (1-11 Months Old)Time frame: from 6 months up to 2.5 years
  3. All-cause Mortality (12-59 Months Old)Time frame: from 6 months up to 2.5 years
  4. Prevalence of Resistance to Macrolides - Nasopharyngeal Swabs (1-59 Months Old)Time frame: After 4 distributions (approximately 24 months)
  5. Load of Genetic Determinants of Resistance to Macrolides - Rectal Swabs (1-59 Months Old)Time frame: After 4 distributions (approximately 24 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Programme national de santé oculaire

    Niamey, Niger

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.